Schering-Plough

Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer

Thursday, September 23, 2021 - 1:00pm

NEW YORK and HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-powered drug discovery company, today announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO) to oversee capital markets, investor relations, financial operations, and corporate development.

Key Points: 
  • NEW YORK and HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-powered drug discovery company, today announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO) to oversee capital markets, investor relations, financial operations, and corporate development.
  • Insilico is leveraging its AI platform to accelerate the research and development process across multiple therapeutic areas, including oncology, immunology, inflammation and infectious diseases," said Mr. Jhaveri.
  • Before joining Insilico, he served as Chief Financial Officer of Journey Medical Corporation, a commercial-stage biopharmaceutical company, where he was responsible for business development, corporate strategy and capital raising.
  • Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and ageing-related diseases.

Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer

Thursday, September 23, 2021 - 1:00pm

NEW YORK and HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-powered drug discovery company, today announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO) to oversee capital markets, investor relations, financial operations, and corporate development.

Key Points: 
  • NEW YORK and HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-powered drug discovery company, today announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO) to oversee capital markets, investor relations, financial operations, and corporate development.
  • Insilico is leveraging its AI platform to accelerate the research and development process across multiple therapeutic areas, including oncology, immunology, inflammation and infectious diseases," said Mr. Jhaveri.
  • Before joining Insilico, he served as Chief Financial Officer of Journey Medical Corporation, a commercial-stage biopharmaceutical company, where he was responsible for business development, corporate strategy and capital raising.
  • Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and ageing-related diseases.

Charles Bodner Joins CSafe Global as Chief Financial Officer

Wednesday, September 15, 2021 - 5:17pm

DAYTON, Ohio, Sept. 15, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner has joined the company's executive team as Chief Financial Officer. 

Key Points: 
  • CSafe Global has hired Charles Bodner as CFO following Patrick Schafer's promotion to CEO in 2020.
  • DAYTON, Ohio, Sept. 15, 2021 /PRNewswire/ -- CSafe Global , the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner has joined the company's executive team as Chief Financial Officer.
  • Prior to joining CSafe Global, he held senior level positions with Sanofi-Aventis, Schering-Plough, AstraZeneca, Becton Dickinson and Bioclinica.
  • "After helping Bioclinica successfully complete its merger with ERT, I am very excited to be joining the CSafe team," Bodner said.

Charles Bodner Joins CSafe Global as Chief Financial Officer

Wednesday, September 15, 2021 - 4:42pm

DAYTON, Ohio, Sept. 15, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner has joined the company's executive team as Chief Financial Officer. 

Key Points: 
  • CSafe Global has hired Charles Bodner as CFO following Patrick Schafer's promotion to CEO in 2020.
  • DAYTON, Ohio, Sept. 15, 2021 /PRNewswire/ -- CSafe Global , the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner has joined the company's executive team as Chief Financial Officer.
  • Prior to joining CSafe Global, he held senior level positions with Sanofi-Aventis, Schering-Plough, AstraZeneca, Becton Dickinson and Bioclinica.
  • "After helping Bioclinica successfully complete its merger with ERT, I am very excited to be joining the CSafe team," Bodner said.

F2G appoints Camilla Soenderby to Board of Directors

Wednesday, September 15, 2021 - 8:00am

MANCHESTER, England, PRINCETON, N.J.and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.

Key Points: 
  • MANCHESTER, England, PRINCETON, N.J.and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.
  • Patrick Vink, Chairman of F2G Ltd, said: "On behalf of the whole board I am very pleased to welcome Camilla to F2G.
  • Camilla began her career as a management consultant at McKinsey & Co. focused on the biopharmaceutical and medical devices industries.
  • F2G is a world-leading biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.

F2G appoints Camilla Soenderby to Board of Directors

Wednesday, September 15, 2021 - 8:00am

MANCHESTER, England, PRINCETON, N.J. and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.   

Key Points: 
  • MANCHESTER, England, PRINCETON, N.J.and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.
  • Patrick Vink, Chairman of F2G Ltd, said: "On behalf of the whole board I am very pleased to welcome Camilla to F2G.
  • Camilla began her career as a management consultant at McKinsey & Co. focused on the biopharmaceutical and medical devices industries.
  • F2G is a world-leading biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.

Leading Across Borders and Business Cultures

Friday, September 3, 2021 - 10:05pm

The session will illuminate how to navigate cultural and regional differences in your workforce, alongside their benefits and challenges.

Key Points: 
  • The session will illuminate how to navigate cultural and regional differences in your workforce, alongside their benefits and challenges.
  • Leading the discussion will be Rich Schatzberg, Chief Commercial Officer at NeSt Technologies, a global software development and services company with offices throughout the US, Europe, the Middle East, India and Asia.
  • "Oftentimes, the growth of your company is contingent on global expansion," said Ken Banta, Founder and Principal of the Vanguard Network.
  • Ken Banta is a top management advisor who works with CEOs and senior executives on leadership, organizational transformation and corporate positioning.

Insilico Medicine Appoints the Former Chief Medical Officer of Schering Plough, Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets

Thursday, September 2, 2021 - 2:00pm

"It is a great opportunity to be joining Insilico Medicine at this time in the company's evolution.

Key Points: 
  • "It is a great opportunity to be joining Insilico Medicine at this time in the company's evolution.
  • Insilico has a broad discovery pipeline based on the identification of critical pathways affecting acute and chronic systems biology in multiple therapy areas.
  • Insilico Medicine offers a unique opportunity to improve the lives of patients with serious and life-threatening disorders.
  • Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and ageing-related diseases.

Insilico Medicine Appoints the Former Chief Medical Officer of Schering Plough, Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets

Thursday, September 2, 2021 - 2:00pm

"It is a great opportunity to be joining Insilico Medicine at this time in the company's evolution.

Key Points: 
  • "It is a great opportunity to be joining Insilico Medicine at this time in the company's evolution.
  • Insilico has a broad discovery pipeline based on the identification of critical pathways affecting acute and chronic systems biology in multiple therapy areas.
  • Insilico Medicine offers a unique opportunity to improve the lives of patients with serious and life-threatening disorders.
  • Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and ageing-related diseases.

Livestock Monitoring Market Size Worth $13.50 Billion By 2028: Grand View Research, Inc.

Thursday, September 2, 2021 - 9:35am

SAN FRANCISCO, Sept. 2, 2021 /PRNewswire/ -- The global livestock monitoring market size is expected to reach USD 13.50 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Sept. 2, 2021 /PRNewswire/ -- The global livestock monitoring market size is expected to reach USD 13.50 billion by 2028, according to a new report by Grand View Research, Inc.
  • An increase in the population of livestock animals, coupled with the farmer's focus on increasing yield and productivity, is the key contributor to the market growth.
  • Factors like these are expected to encourage the adoption of livestock monitoring systems among livestock owners.
  • Grand View Research has segmented the global livestock monitoring market on the basis of animal type, component, application, and region:
    Livestock Monitoring Animal Type Outlook (Revenue, USD Million, 2016 - 2028)